Tags

Type your tag names separated by a space and hit enter

Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions.
Clin Pharmacol Drug Dev. 2020 Jul; 9(5):593-601.CP

Abstract

To assess the bioequivalence of two 5-mg olanzapine orally disintegrating tablet (ODT) products, 2 randomized, open-label, single-dose, 2-way crossover studies were carried out under fasting or fed conditions. Blood samples were collected at scheduled times according to the study protocol. Statistical analysis of area under the concentration-time curve from time 0 to 168 hours (AUC0-t), area under the curve from time zero to infinity (AUC0-∞), and peak plasma concentration (Cmax) was conducted. Two formulations were considered bioequivalent if the 90% confidence intervals (CIs) of the geometric mean ratios for AUC0-t, AUC0-∞ , and Cmax were within the range of 0.80-1.25. Adverse events were recorded and evaluated throughout the studies. A total of 48 subjects with 24 in each study completed the 2 studies. In fasted subjects, the 90%CIs for the test product versus the reference product were 97.28%-105.13% for AUC0-t , 97.57%-105.54% for AUC0-∞ , and 90.94%-103.97% for Cmax . In fed subjects, the 90%CIs for AUC0-t , AUC0-∞ and Cmax were 99.73%-122.63%, 99.56%-121.75%, and 99.46%-120.46%, respectively. No serious adverse events were reported in the studies. The reference and the test product of 5-mg olanzapine ODT show comparable pharmacokinetic profiles under both fed and fasted conditions and were considered bioequivalent.

Authors+Show Affiliations

Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.QILU Pharmaceutical, Jinan, Shandong, China.Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32413238

Citation

Fan, Lin, et al. "Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions." Clinical Pharmacology in Drug Development, vol. 9, no. 5, 2020, pp. 593-601.
Fan L, Zhang L, Zheng H, et al. Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions. Clin Pharmacol Drug Dev. 2020;9(5):593-601.
Fan, L., Zhang, L., Zheng, H., Cheng, J., Hu, Y., Liu, J., & Fan, H. (2020). Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions. Clinical Pharmacology in Drug Development, 9(5), 593-601. https://doi.org/10.1002/cpdd.765
Fan L, et al. Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions. Clin Pharmacol Drug Dev. 2020;9(5):593-601. PubMed PMID: 32413238.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions. AU - Fan,Lin, AU - Zhang,Lizhi, AU - Zheng,Hongquan, AU - Cheng,Junlin, AU - Hu,Yunfang, AU - Liu,Jianghui, AU - Fan,Hongwei, Y1 - 2020/05/15/ PY - 2019/07/14/received PY - 2019/11/19/accepted PY - 2020/5/16/pubmed PY - 2020/5/16/medline PY - 2020/5/16/entrez KW - bioequivalence KW - olanzapine KW - orally disintegrating tablets KW - pharmacokinetics SP - 593 EP - 601 JF - Clinical pharmacology in drug development JO - Clin Pharmacol Drug Dev VL - 9 IS - 5 N2 - To assess the bioequivalence of two 5-mg olanzapine orally disintegrating tablet (ODT) products, 2 randomized, open-label, single-dose, 2-way crossover studies were carried out under fasting or fed conditions. Blood samples were collected at scheduled times according to the study protocol. Statistical analysis of area under the concentration-time curve from time 0 to 168 hours (AUC0-t), area under the curve from time zero to infinity (AUC0-∞), and peak plasma concentration (Cmax) was conducted. Two formulations were considered bioequivalent if the 90% confidence intervals (CIs) of the geometric mean ratios for AUC0-t, AUC0-∞ , and Cmax were within the range of 0.80-1.25. Adverse events were recorded and evaluated throughout the studies. A total of 48 subjects with 24 in each study completed the 2 studies. In fasted subjects, the 90%CIs for the test product versus the reference product were 97.28%-105.13% for AUC0-t , 97.57%-105.54% for AUC0-∞ , and 90.94%-103.97% for Cmax . In fed subjects, the 90%CIs for AUC0-t , AUC0-∞ and Cmax were 99.73%-122.63%, 99.56%-121.75%, and 99.46%-120.46%, respectively. No serious adverse events were reported in the studies. The reference and the test product of 5-mg olanzapine ODT show comparable pharmacokinetic profiles under both fed and fasted conditions and were considered bioequivalent. SN - 2160-7648 UR - https://www.unboundmedicine.com/medline/citation/32413238/Pharmacokinetics_and_Bioequivalence_of_2_Olanzapine_Orally_Disintegrating_Tablet_Products_in_Healthy_Chinese_Subjects_Under_Fed_and_Fasting_Conditions L2 - https://doi.org/10.1002/cpdd.765 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.